The value of estimating serum apoptotic marker concentrations in the monitoring and prognosis of 131I - Therapy in Graves' disease. Preliminary report

Nuclear Medicine Review

Volumn 7, Issue 2, 2004, Pages 117-122

  Rogowski, Franciszek ^a   Parfieńczyk, Adam ^a   Sopotyk, Antoni ^a   Budlewski, Tadeusz ^a   Jabłońska, Ewa ^a   Kiersnowska Rogowska, Beata ^a   Szumowski, Piotr ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

131I therapy; Apoptosis; Graves' disease

Indexed keywords

BIOLOGICAL MARKER; FAS ANTIGEN; FAS LIGAND; IODINE 131; LIOTHYRONINE; PROTEIN BCL 2; THYROTROPIN; THYROXINE;

ADULT; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DRUG MECHANISM; EUTHYROIDISM; FEMALE; FREE LIOTHYRONINE INDEX; FREE THYROXINE INDEX; GRAVES DISEASE; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; MALE; MORPHOLOGY; PATIENT MONITORING; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RADIATION DOSE; RADIOTHERAPY; THYROID FUNCTION;

ADULT; ANTIGENS, CD95; APOPTOSIS; BIOLOGICAL MARKERS; BLOOD PROTEINS; FAS LIGAND PROTEIN; FEMALE; GRAVES DISEASE; HUMANS; IODINE RADIOISOTOPES; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PILOT PROJECTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 12344307276     PISSN: 15069680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Lind P. Strategies of radioiodine therapy for Graves' disease. Eur J Nucl Med 2002; 29: Suppl. 2, 453-457.
2. Wartowsky L. Radioodine therapy for Graves' disease: case selection and restrictions recommended to patients in North America Thyroid 1997; 7: 213-216.
3. Rogowski F., Jurgilewicz D.H. Praktyczne aspekty radioizotopowego leczenia nadczynności tarczycy. Pol Merk Lek 1999; 6: 347-359.
4. Marinelli L.D., Quimby E.H., Heine G.J. Dosage determination with radioactive isotopes. Practical considerations in therapy and protection. Am J Roentgenol 1948; 59: 260-281.
5. Meller J., Sahlamann C.O., Becker W. Radioiodine - treatment (RIT) of functional thyroidal autonomy. Nucl Med Rev 2002; 5: 1-10.
6. Janiak M.K., Wrembel-Wargocka J., Cheda A. Apoptoza popromienna - mechanizmy, rola biologiczna i możliwości wykorzystania w terapii nowotworów. Post Biol Kom 1999; 26: 285-310.
7. Kawakami A, Eguchi K, Matsuoka N, et al. Modulation of Fas-mediated apoptosis of human thyroid epithelial cells by IgG from patients with Graves' disease (GD) and idiopathic myxoedema. Clin Exp Immunol 1997; 110: 434-439.
8. Dayan C.M., Daniels G.H. Chronic autoimmune thyroiditis. N Engl J Med 1996; 335: 99-107.
9. Smolewski P. Rola kaspaz w procesie apoptozy. Post Hig Med Dośw 2003; 57: 3, 335-254.
10. Ashkenazi A., Dixit V.M. Death receptors: signalling and modulation. Science 1998; 281: 1305-1308.
11. Koga M., Hiromatsu Y., Jimi A., Toda S., Koike N., Nonaka K. Immunohistochemical analisys of Bcl-2, Bax and Bak expression in thyroid glands from patients with subacute thyroiditis. J Clin Endocrinol Metab 1999; 84: 2221-2225.
12. Wang C.Y., Zhong W.B., Chang T.C., Tsai Y.F. Circulating soluble Fas ligand correlates with disease activity in Graves' hyperthyroidism. Metabolism 2002; 51: 769-773.
13. Chang J, Zhou T, Liu C. et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994; 263: 1759-1762.
14. Feldkamp J., Pascher E., Schott M., Goretzki P., Seissler J., Scherbaum W.A. Soluble Fas is increased in hyperthyroidism independent of the underlying thyroid disease. J Clin Endocrinol Metab 2001; 86: 4250-4253.
15. Hiromatsu Y, Bednarczuk T, Soyejima E. et al. Increased serum soluble Fas in patients with Graves' disease. Thyroid 1999; 9: 341-345.
16. Giordano C., Richiusa P., Bagnasco M. et al. Differential regulation of Fas-mediated apoptosis in both thyrocyte and lymphocyte cellular compartments correlated with opposite phenotypic manifestations of autoimmune thyroid disease. Thyroid 2001; 11: 245-247.
17. Rogowski F., Parfieńczyk A., Budlewski T. et al. Zmiany steżeń głównych czynników proapoptotycznych - Fas, FasL i antyapoptotycznego Bcl-2 w monitorowaniu radiojodoterapia chorych z choroba Graves'a-Basedova. Probl Med Nukl 2004; 18: 17-18.
18. 131I therapy of Graves' disease and serum concentration of selected apoptotic markers as prognostic factor. Eur J Nucl Med Mol Imag 2004; 31: suppl. 2, 371,
19. Palazzo FF., Hammond LJ., Gook AW., Misakian R. Death of the autoimmune thyrocyte: is it pushed or does it jump? Thyroid 2000; 10: 561-572.
20. Lin JD. The role of apoptosis in autoimmune thyroid disorders and thyroid cancer. BMJ 2001; 322: 1525-1527.
21. Andrikoula M., Tsatoulis A. The role of Fas-mediated in thyroid disease. Eur J Endocrinol 2001; 144: 561-568.
22. Sera N, Kawakami A, Nakashima T. et al. Fas/FasL mediated apoptosis of thyrocytes in Graves' disease. Clin Exp Immunol 2001; 124: 197-207.
23. Vlaeminck-Guillem V, d'Herbomer-Boiden M, Decoulx M, Wemean JL. Apoptosis and the thyroid: the Fas pathway. Press Med 2001; 30: 74-80.
24. Lumachi F., Basso S. Apoptosis: Life through planned cellular death regulating mechanisms control systems and relations with thyroid diseases. Thyroid 2002; 12: 27-34.
25. Olive PL, Durand RE. Apoptosis: an indicator of radiosensitivity in vitro? Int J Radiat Biol 1997; 71: 685-701.
26. Sopotyk A, Rogowski F, Parfieńczyk A. Apoptosis: its pathophisiology and monitoring. The role of apoptosis in the radioiodine therapy of hyperthyroidism. Nucl Med Rev 2004; 7: 1, 53-58.